Akash Tewari
Stock Analyst at Jefferies
(4.76)
# 617
Out of 4,646 analysts
500
Total ratings
59.9%
Success rate
13.7%
Average return
Main Sectors:
Stocks Rated by Akash Tewari
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals | Maintained: Buy | $610 → $633 | $522.14 | +21.23% | 4 | Aug 11, 2026 | |
| DMRA Damora Therapeutics | Maintained: Buy | $50 | $31.01 | +61.24% | 2 | Aug 11, 2026 | |
| JBIO Jade Biosciences | Maintained: Buy | $40 → $48 | $23.50 | +104.26% | 3 | Aug 11, 2026 | |
| BMRN BioMarin Pharmaceutical | Maintained: Buy | $104 | $68.78 | +51.22% | 38 | Aug 7, 2026 | |
| PFE Pfizer | Maintained: Buy | $34 | $26.77 | +27.01% | 45 | Aug 5, 2026 | |
| BNTX BioNTech SE | Maintained: Buy | $138 | $92.70 | +48.87% | 38 | Aug 4, 2026 | |
| NBIX Neurocrine Biosciences | Maintained: Buy | $200 | $151.79 | +31.76% | 29 | Jul 30, 2026 | |
| LON: 0QW0 argenx SE | Maintained: Buy | n/a | $756.00 | - | 4 | Jul 23, 2026 | |
| IONS Ionis Pharmaceuticals | Maintained: Buy | $90 | $55.85 | +61.15% | 10 | Jul 15, 2026 | |
| ALKS Alkermes | Maintained: Buy | $59 → $65 | $49.75 | +30.65% | 28 | Jul 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $1,350 | $1,210.00 | +11.57% | 45 | Jul 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $98 | $102.71 | -4.59% | 5 | Jun 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $180 | $136.78 | +31.60% | 2 | May 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $14 | $4.06 | +244.83% | 1 | Apr 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $885 → $890 | $810.57 | +9.80% | 35 | Mar 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $350 | $418.31 | -16.33% | 2 | Mar 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $980 → $1,008 | $864.04 | +16.66% | 42 | Feb 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $50 → $46 | $50.84 | -9.52% | 19 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $26 → $35 | $16.84 | +107.85% | 2 | Dec 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $13 → $42 | $25.74 | +63.17% | 6 | Nov 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $18 → $20 | $13.85 | +44.40% | 8 | Oct 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $70 → $80 | $74.48 | +7.41% | 19 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $398 → $502 | $517.50 | n/a | 16 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $86 → $96 | $134.54 | n/a | 4 | Jul 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $138 | $134.71 | n/a | 34 | Jun 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $52 → $10 | $8.95 | n/a | 8 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $70 → $68 | $64.85 | n/a | 13 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $183 | $246.05 | n/a | 18 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $6 → $2.5 | $4.24 | n/a | 7 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $16 → $17 | $20.06 | n/a | 7 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $17 | $1.83 | n/a | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $16.26 | n/a | 2 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $8.74 | n/a | 2 | Jan 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $9 | $37.12 | n/a | 1 | Jul 19, 2019 |
Vertex Pharmaceuticals
Aug 11, 2026
Maintained: Buy
Price Target: $610 → $633
Current: $522.14
Upside: +21.23%
Damora Therapeutics
Aug 11, 2026
Maintained: Buy
Price Target: $50
Current: $31.01
Upside: +61.24%
Jade Biosciences
Aug 11, 2026
Maintained: Buy
Price Target: $40 → $48
Current: $23.50
Upside: +104.26%
BioMarin Pharmaceutical
Aug 7, 2026
Maintained: Buy
Price Target: $104
Current: $68.78
Upside: +51.22%
Pfizer
Aug 5, 2026
Maintained: Buy
Price Target: $34
Current: $26.77
Upside: +27.01%
BioNTech SE
Aug 4, 2026
Maintained: Buy
Price Target: $138
Current: $92.70
Upside: +48.87%
Neurocrine Biosciences
Jul 30, 2026
Maintained: Buy
Price Target: $200
Current: $151.79
Upside: +31.76%
argenx SE
Jul 23, 2026
Maintained: Buy
Price Target: n/a
Current: $756.00
Upside: -
Ionis Pharmaceuticals
Jul 15, 2026
Maintained: Buy
Price Target: $90
Current: $55.85
Upside: +61.15%
Alkermes
Jul 9, 2026
Maintained: Buy
Price Target: $59 → $65
Current: $49.75
Upside: +30.65%
Jul 6, 2026
Maintained: Buy
Price Target: $1,350
Current: $1,210.00
Upside: +11.57%
Jun 30, 2026
Maintained: Buy
Price Target: $98
Current: $102.71
Upside: -4.59%
May 22, 2026
Maintained: Buy
Price Target: $180
Current: $136.78
Upside: +31.60%
Apr 30, 2026
Maintained: Buy
Price Target: $14
Current: $4.06
Upside: +244.83%
Mar 11, 2026
Maintained: Buy
Price Target: $885 → $890
Current: $810.57
Upside: +9.80%
Mar 10, 2026
Initiated Coverage: Hold
Price Target: $350
Current: $418.31
Upside: -16.33%
Feb 19, 2026
Maintained: Buy
Price Target: $980 → $1,008
Current: $864.04
Upside: +16.66%
Dec 11, 2025
Maintained: Buy
Price Target: $50 → $46
Current: $50.84
Upside: -9.52%
Dec 5, 2025
Maintained: Buy
Price Target: $26 → $35
Current: $16.84
Upside: +107.85%
Nov 17, 2025
Maintained: Buy
Price Target: $13 → $42
Current: $25.74
Upside: +63.17%
Oct 1, 2025
Upgraded: Buy
Price Target: $18 → $20
Current: $13.85
Upside: +44.40%
Sep 3, 2025
Reiterated: Buy
Price Target: $70 → $80
Current: $74.48
Upside: +7.41%
Aug 12, 2025
Maintained: Buy
Price Target: $398 → $502
Current: $517.50
Upside: n/a
Jul 8, 2025
Maintained: Buy
Price Target: $86 → $96
Current: $134.54
Upside: n/a
Jun 18, 2025
Maintained: Buy
Price Target: $138
Current: $134.71
Upside: n/a
May 2, 2025
Downgraded: Hold
Price Target: $52 → $10
Current: $8.95
Upside: n/a
Apr 23, 2025
Maintained: Buy
Price Target: $70 → $68
Current: $64.85
Upside: n/a
Apr 1, 2025
Maintained: Buy
Price Target: $183
Current: $246.05
Upside: n/a
Jan 29, 2025
Maintained: Hold
Price Target: $6 → $2.5
Current: $4.24
Upside: n/a
Dec 11, 2024
Rated: Buy
Price Target: $16 → $17
Current: $20.06
Upside: n/a
Dec 12, 2022
Initiated Coverage: Buy
Price Target: $17
Current: $1.83
Upside: n/a
Feb 26, 2021
Downgraded: Hold
Price Target: n/a
Current: $16.26
Upside: n/a
Jan 29, 2020
Downgraded: Hold
Price Target: n/a
Current: $8.74
Upside: n/a
Jul 19, 2019
Initiated Coverage: Hold
Price Target: $9
Current: $37.12
Upside: n/a